SKU:  PME101564     Target:  CDH17

Price: 10μg $72.00; 50μg $272.00; 100μg $409.00

SKU:  PME101566     Target:  CDH17

Price:10μg $95.00 ; 50μg $330.00 ; 100μg $500.00

SKU:  PME100199     Target:  CDH17

Price: 10μg $75.00; 50μg $259.00 ; 100μg $389.00

SKU:  PME101384     Target:  CDH17

Price: 10μg $75.00; 50μg $259.00 ; 100μg $389.00

SKU:  PME101623     Target:  CDH17

Price:10μg $100.00 ; 50μg $358.00 ; 100μg $528.00

SKU:  PME101563     Target:  CDH17

Price:10μg $95.00 ; 50μg $330.00 ; 100μg $500.00

SKU:  PME101567     Target:  CDH17

Price:10μg $100.00 ; 50μg $358.00 ; 100μg $528.00

SKU:  PME101565     Target:  CDH17

Price:10μg $100.00 ; 50μg $358.00 ; 100μg $528.00

SKU:  PME101608     Target:  CDH17

Price: 10μg $68.00; 50μg $259.00 ; 100 μg $389.00

SKU:  PME101562     Target:  CDH17

Price:10μg $100.00 ; 50μg $358.00 ; 100μg $528.00

SKU:  PME100801     Target:  CDH17

Price: 10μg $72.00; 50μg $272.00; 100μg $409.00

SKU:  PME-M100098     Target:  CDH17

Price: 10μg $70.00; 50μg $244.00 ; 100μg $367.00

SKU:  PME-C100029     Target:  CDH17

Price:10μg $95.00; 50μg $330.00; 100μg $500.00


Posts found

CDH17 ADCs blooms in 2025 AACR

The 116th AACR Annual Meeting will be held from April 25 to 30, 2025, at [...]

CDH17: A Target for Diverse Solid Tumor Therapies—Will It Lead to Significant Breakthroughs in Cancer Treatment?

In March 2022, a study published in Nature Cancer highlighted Cadherin 17 (CDH17) as an [...]

Popular Targets in the Bispecific ADC Pipeline

At the 2025 AACR Annual Meeting, Chinese ADC drugs have emerged in various forms such [...]

Dual-Function Reagent for ADC Screening: Evaluating Internalization and Cytotoxicity in One Step

In recent years, Antibody-Drug Conjugates (ADCs) have gained widespread attention as a key strategy in [...]

China’s Growing Impact on ADC Development at AACR 2025

The 2025 American Association for Cancer Research (AACR) Annual Meeting is set to take place [...]

CDH6 ADC: Promising Results for Ovarian Cancer Treatment!

In March 2024, a preclinical study titled “Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a [...]

FRα/FOLR1 – Another Anti-cancer Target Fueled by the ADC

Folate receptor alpha (FRα), due to its differential expression in various tumor or cancer tissues [...]

Navigating the ADC Frontier: Unleashing the Magic of Antibody-Drug Conjugates

Antibody-drug conjugates (ADCs) have been one of the hottest areas in the biopharmaceutical industry in [...]